Debio 4127 is sustained-release formulation designed to improve the performance and convenience of somatostatin analogue (SSA) therapy for the treatment of Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The safety and efficacy of this SSA 3-month formulation is currently under investigation. The application of Debiopharm’s novel injectable sustained release would reduce injection frequency from once every 4 weeks to once every 12 weeks. Debiopharm is seeking partners with expertise in rare diseases/orphan drugs and/or in endocrinology or oncology for the further development of this compound in order to dramatically improve convenience for GEP-NET patients
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare and complex neoplasms that present many clinical challenges for patients. About two-thirds of neuroendocrine tumors occur in the gastroenteropancreatic system, involving mainly the stomach, small intestine, colon, appendix, rectum, and pancreas. Most GEP-NETs are sporadic, but sometimes stem from familial syndrome. Some may be more aggressive and associated with poor prognosis while others remain fairly indolent. Treatment aims to remove the tumors, reduce or halt their growth and spread, along with providing symptom relief of excessive hormone production (known as carcinoid syndrome). As the majority of patients are not eligible for curative surgery at the time of diagnosis, they can be offered long-term systemic treatment including somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT), chemotherapy, etc., alone or combined with cytoreductive procedures. A 12-week SSA formulation would increase patient convenience and compliance.